Annual General Meeting 2016 and Nomination Committee
The Annual General Meeting of NeuroVive Pharmaceutical AB (publ) will be held on 28 April 2016 at 4 p.m. at Medicon Village, Scheelevägen 2, in Lund, Sweden.
Press releases
NeuroVive announces departure of CEO and appointment of Jan Nilsson as interim CEO
NeuroVive Pharmaceutical AB (publ), the mitochondrial medicine company, announces a change in leadership of the company. Effective today, Mikael Brönnegård will no longer serve as Chief Executive Off ...
NeuroVive refocuses CicloMulsion development – discontinues acute myocardial infarction indication
CicloMulsion® development to continue in acute kidney injury and increased focus on development of other drug candidates. Shareholder information meeting to be held on 10th September 2015 in Lund, Swe ...
NeuroVive reports topline results of phase III CIRCUS study in acute myocardial infarction
NeuroVive Pharmaceutical AB (publ), the mitochondrial medicine company, reports that the phase III CIRCUS study of CicloMulsion® in patients with a specific type of heart attack known as ST-segment el ...
NeuroVive Asia signs collaboration agreement with Sanofi for the development and commercialization of CicloMulsion® in South Korea
NeuroVive Pharmaceutical AB (publ), the mitochondrial medicine company, announces that NeuroVive Pharmaceutical Asia group has signed a collaboration agreement with Sanofi's local affiliate for the de ...
Sale of shares off the market following share exchange program
NeuroVive Pharmaceutical AB (publ), the mitochondrial medicine company, announces that one of its insider registered persons has executed a limited share sale following completed share swaps from Maas ...
Topline result of Phase III study of CicloMulsion® in acute myocardial infarction expected this quarter
NeuroVive Pharmaceutical AB (publ), the mitochondrial medicine company, expects to announce the topline result of the phase III CIRCUS study of CicloMulsion® in patients with a specific type of heart ...
Published data indicates protective effect of cyclosporine in patients with stroke
The results of a clinical phase II study indicating that cyclosporine counteracts brain injury in a subset of stroke patients undergoing thrombolysis has been published in an article co-authored by on ...
First patient enrolled in clinical phase II study for kidney protection during heart surgery
NeuroVive Pharmaceutical AB (publ), the mitochondrial medicine company, announces that the first patient has been enrolled in a clinical phase II study for acute kidney injury using the company's prod ...
Clinical Phase II study with NeuroSTAT® for traumatic brain injury passes safety evaluation
NeuroVive Pharmaceutical AB (publ), the mitochondrial medicine company, announces that the independent safety committee has endorsed moving on to the next dose level without any safety issues, followi ...
NeuroVive establishes subsidiary in Lyon and extends collaboration with HCL
NeuroVive Pharmaceutical AB (publ), the mitochondrial medicine company, has established a subsidiary in Lyon, France. The establishment is part of a process of extending its ongoing collaboration with ...
Development of NVP014 for the treatment of stroke enters new phase in collaboration with Isomerase Therapeutics
NeuroVive Pharmaceutical AB (publ), the mitochondrial medicine company, has announced that the company's development project NVP014 for the treatment of ischemic stroke is entering a new phase in coll ...